title: 90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
abstract: (90) Y-ibritumomab-tiuxetan ((90) YIT) was used as a first-line therapy for patients with early-stage follicular lymphoma (FL) or marginal zone B-cell lymphoma (MZL). Thirty-one patients were treated, with an overall 3-month response rate of 100% (68% complete response, 29% unconfirmed complete response and 3% partial response). At a median follow-up of 56 months, ten patients (32%) had disease relapse or progression. The progression-free rates at 3 and 5 years were lower in males, patients with FL, stage II disease and non-bulky disease, although they did not reach statistical significance. Grade 3-4 neutropenia, thrombocytopenia and anaemia were 61%, 35%, and 3%, respectively. (90) YIT was well tolerated, including in those patients over 60 years old, and achieved high response rates in patients with early-stage low-grade B-cell lymphomas. Bulky disease did not adversely affect tumour response.
authors.affiliation: Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors.forename: Felipe
authors.initials: F
authors.lastname: Samaniego
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Berkova
authors.forename: Jorge E
authors.initials: JE
authors.lastname: Romaguera
authors.forename: Nathan
authors.initials: N
authors.lastname: Fowler
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Fanale
authors.forename: Barbara
authors.initials: B
authors.lastname: Pro
authors.forename: Jatin J
authors.initials: JJ
authors.lastname: Shah
authors.forename: Peter
authors.initials: P
authors.lastname: McLaughlin
authors.forename: Lalit
authors.initials: L
authors.lastname: Sehgal
authors.forename: Vijairam
authors.initials: V
authors.lastname: Selvaraj
authors.forename: Frank K
authors.initials: FK
authors.lastname: Braun
authors.forename: Rohit
authors.initials: R
authors.lastname: Mathur
authors.forename: Lei
authors.initials: L
authors.lastname: Feng
authors.forename: Sattva S
authors.initials: SS
authors.lastname: Neelapu
authors.forename: Larry W
authors.initials: LW
authors.lastname: Kwak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000473:pathology / Q000532:radiotherapy*; D008224:Lymphoma, Follicular / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011832:Radiation Injuries / Q000209:etiology; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods; D016019:Survival Analysis; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan
keywords: follicular; marginal zone; myelosuppression; radiation; zevalin